Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OncLive Global Expo
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2019 AACR Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Patel on Benefit of Ipilimumab/Nivolumab Combo in High-Grade Neuroendocrine Carcinoma
Dr. Sequist on Rationale for TATTON Trial in EGFR-Mutant Lung Cancer
Association Between BMI and Pancreatic Cancer Mortality
Oncology Conference Articles
Surgery Linked With Improved OS in HER2+ Advanced Breast Cancer
Primary tumor surgery for patients with stage IV HER2-positive breast cancer is associated with an improvement in overall survival, according to results of a retrospective cohort review presented at the 2019 AACR Annual Meeting.
LOXO-195 Active After Initial Anti-TRK Failure in Multiple Tumor Types
A third of patients with advanced TRK fusion tumors had objective responses to the second-generation TRK inhibitor LOXO-195 after failure of initial anti-TRK therapy.
Rucaparib Maintenance Shows Early Efficacy in Pancreatic Cancer
Maintenance therapy with rucaparib maintained disease control and was well tolerated in patients with platinum-sensitive, advanced
-mutant pancreatic cancer, according to preliminary interim findings of a single-arm, phase II trial.
Data Support TMB as Marker for Durvalumab Activity in NSCLC
Tumor mutational burden identified patients who obtained a survival benefit with the PD-L1 inhibitor durvalumab, as initial therapy versus chemotherapy for advanced non–small cell lung cancer, even though the primary analysis of the randomized trial showed no difference between treatment groups, according to a new analysis.
Pembrolizumab Shows Promising Antitumor Activity in Pretreated Patients With SCLC
Pembrolizumab (Keytruda) demonstrated promising antitumor activity with durable responses in patients with pretreated advanced small cell lung cancer.
Gilteritinib Improves OS in Relapsed/Refractory FLT3+ AML
Gilteritinib was found to significantly improve overall survival in patients with relapsed/refractory
mutation–positive acute myeloid leukemia, according to updated findings of the phase III ADMIRAL trial.
Umbralisib Achieves Impressive ORR in Relapsed/Refractory MZL
The PI3K-delta inhibitor umbralisib was found to demonstrate an overall response rate of 52% and show an encouraging tolerability profile in patients with relapsed/refractory marginal zone lymphoma, according to findings from a cohort of the phase IIb UNITY-NHL trial.
T-VEC Plus Chemo Hits High pCR Rate in TNBC
A majority of patients with large triple-negative breast tumors achieved pathologic complete response when treated with the viral oncolytic talimogene laherparepvec plus neoadjuvant chemotherapy.
Osimertinib/Savolitinib Pairing Is Active in Relapsed EGFR-Mutant, MET-Amplified NSCLC
The combination of osimertinib and the MET inhibitor savolitinib demonstrated encouraging clinical activity and an acceptable risk-benefit profile in patients with
-amplified non–small cell lung cancer who previously received EGFR TKIs.
Nivolumab/Ipilimumab Active in High-Grade Neuroendocrine Tumors
The immune checkpoint inhibitor combination of nivolumab and ipilimumab induced a greater than 40% response rate and was well tolerated in patients with high-grade neuroendocrine carcinoma.
CAR T Cells Targeting Mesothelin Show Strong Early Signal in Advanced Solid Cancers
CAR T cells targeting mesothelin-expressing tumors demonstrated safety and efficacy in a preliminary clinical evaluation in patients with malignant pleural disease.
CAR T-Cell Therapy and Lymphodepletion Shows Early Efficacy, Tolerability in Advanced Sarcoma
The administration of HER2-directed CAR T-cell therapy and lymphodepletion chemotherapy demonstrated antitumor activity and was found to be safe in pediatric and adult patients with advanced HER2-positive sarcoma.
Pre-existing Cardiovascular Disease Linked to Higher Mortality With Abiraterone
Pre-existing cardiovascular disease was associated with an increased mortality risk during the first 6 months of abiraterone acetate treatment in patients with advanced prostate cancer.
Younger Patients With CRC Misdiagnosed, Diagnosed at Later Stages
Many younger patients see more than one doctor and face misdiagnoses before being given a diagnosis of colorectal cancer.
Study Validates Speed, Accuracy of Liquid Biopsies Identifying NSCLC Biomarkers
A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non–small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.
Diet May Impact Response to Immunotherapy in Patients With Melanoma
Select patients with melanoma who consume a diet rich in fiber could see an improved response to treatment with immunotherapy.
FDA Approvals in Myeloma and ITP, Applications Accepted in Myeloma and More
Dr. Shadman on the CLL14 Trial in CLL
Expert Highlights Need for Widespread Liquid Biopsy Use in Lung Cancer Treatment
Key Trials Showcase the Utility of Neratinib in HER2+ Breast Cancer
Evaluating Surgery and Angiogenesis Inhibition in Recurrent Ovarian Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.